BRAF and metastatic melanoma: Preclinical evidence of enhanced apoptosis and delayed resistance to BRAF (Rapidly Accelerated Fibrosarcoma, B-family) inhibitors (Paraiso et al., 2010; Flaherty et al., 2012), for example, prompted the FDA to approve a combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) for the treatment of metastatic melanoma with BRAF mutations (Robert et al., 2015; Wahid et al., 2018).